Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Spepharm AG is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions involve 2 distinct examiners and 2 distinct art units. The data shows that the 2 pending office actions are being reviewed independently by different examiners in separate units.
SOROUSH, LAYLA is the busiest examiner for the portfolio, managing 1 busiest examiner pending office action. The total workload of 2 pending office actions is shared between the 2 distinct examiners identified in the data. Because the company interacts with 2 distinct art units, the prosecution strategy must account for the different supervisory structures associated with each unit. The 1 busiest examiner pending office action represents half of the company's current pending workload at the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18503401 | AQUEOUS COMPOSITION COMPRISING DANTROLENE | SOROUSH, LAYLA | — |
| 18559213 | PHARMACEUTICAL FORMULATIONS | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18503401 | AQUEOUS COMPOSITION COMPRISING DANTROLENE | SOROUSH, LAYLA | 1622 | §103DP | Final Rejection | — | Pending | Nov 07, 2023 |
| 18559213 | PHARMACEUTICAL FORMULATIONS | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Final Rejection | — | Pending | Nov 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSpepharm AG has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Layla Soroush has the most, with 1 of Spepharm AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
